Plain-English translation of NCT06262139 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new MRI contrast agent called MT218 that's designed to help doctors spot aggressive prostate cancer more clearly on imaging scans. The medication works by targeting specific markers that appear in aggressive prostate cancers. Researchers want to see if this approach is safe and works better than standard MRI scans at finding cancer that needs treatment.
Current MRI scans sometimes miss aggressive prostate cancer or can't clearly tell the difference between aggressive and less dangerous forms of the disease. This medication could help doctors identify which cancers are most dangerous, leading to better treatment decisions for patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll receive a single injection of the new contrast agent while lying in an MRI machine for a standard imaging scan. The study is divided into three small groups of four patients each, with each group receiving a slightly different dose of the medication to test safety. Your scan results will be compared with your standard MRI, PET scan results, and the findings from your upcoming prostate surgery to see how well the new technique works.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States
Phase
Safety & dosing / Early efficacy
Sponsor
Songqi Gao
Collaborators
Emory University
Enrollment target
~12 participants
Started
July 2024
Primary completion
December 2026
Age range
18 Years – 90 Years
Sex
Male only
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
David M Schuster, MD
Emory University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.